by sfrazee | Mar 21, 2024
By Tomas J. Philipson & Casey B. Mulligan March 21, 2024 Public health frequently trivializes prevention costs, and therefore misjudges the overall effects of disease policies. This month marks the fourth anniversary of the proclamation on March 13, 2020,...
by sfrazee | Mar 15, 2024
By Scott W. Atlas, Steve H. Hanke, Philip G. Kerpen, and Casey B. Mulligan March 2024 Executive Summary This report reviews the major policy errors and lessons learned during the COVID pandemic from a balanced perspective that includes health, economic,...
by sfrazee | Mar 15, 2024
By Tomas Philipson March 15, 2024 As part of its “Strike Force on Unfair and Illegal Pricing,” the White House just doubled down on a December plan to allow the federal government to tear up exclusive patent agreements between innovative drug companies and...
by susuguo | Dec 19, 2023
By Tomas J. Philipson Regarding your editorial “Biden Ambushes Pharma Patents” (Dec. 11): The Biden administration has caved to progressive activists who ignore that America’s pharma and biotech industries are the world leader in bringing innovative therapies to...